Membership is open to all those with an interest in the quality and integrity of scientific research and development and those working with, or interested in, Good Laboratory, Clinical or Manufacturing Practice regulations or Pharmacovigilance, be they from industry, government, academia or contract research and wherever in the world they are based.
Welcome to the RQA website
As an Association dedicated to informing and advancing its members, we provide status and visibility for individuals concerned with the quality of research in pharmaceuticals, agrochemicals, chemicals and medical devices. Since its beginnings in 1977, the Association has grown and developed to reflect regulatory changes, the impact of regulatory inspection and the changing structure and needs of industry. RQA's purpose is to drive quality and integrity in scientific research and development.
Click here to view our vision and mission statement.
2015 Annual Conference
The RQA 2015 Annual Conference will be held at the Queens Hotel, Leeds on the 11-13 November 2015.
Delegate information and booking information will be available soon.
NEW Webcast available now - Clinical Investigators EU Clinical Trials Regulation
This webcast introduces the GCP aspects of the new EU Clinical Trial Regulation 536/2014, and specifically how they impact Clinical Investigators and their site staff. The webcast is for Clinical Investigators, at investigator sites throughout Europe, who work on sponsored clinical trials (commercial and non-commercial), on Investigational Medicinal Products.
Latest News Items
MHRA GMP Data Integrity Definitions and Guidance for Industry March 2015
Data integrity is fundamental in a pharmaceutical quality system which ensures that medicines are of the required quality. This document provides MHRA guidance on GMP data integrity expectations for the pharmaceutical industry.
Use of Electronic Informed Consent in Clinical Investigations Questions and Answers Guidance for Industry
DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft document should be submitted within 60 days of publication in the Federal Register of the notice announcing the availability of the draft guidance.